Nordic Nanovector has successfully completed a 250 MNOK pre-IPO private placement. The private placement was significantly oversubscribed.

The Company intends to use the net proceeds of the private placement to fund further clinical development of BetalutinTM for treatment of non-Hodgkin Lymphoma.